- US seeks 30,000 volunteers for clinical trial of potential vaccine AstraZeneca and Oxford University
- The trial is primarily designed to determine whether the potential vaccine can prevent symptomatic COVID-19 after two doses.
- AstraZeneca’s vaccine is in the final phase before receiving its approval from regulatory authorities
The United States seeks to recruit some 30,000 volunteers in 80 parts of the country to participate in phase 3 of the clinical trial of the possible vaccine in which the pharmaceutical company AstraZeneca and the University of Oxford are working, according to the Efe agency.
The announcement was made this Monday National Institute of Allergy and Infectious Diseases (NIAID) in a statement.
The report that details that the test is part of the operation “Warp Speed” (speed of light), with which the United States seeks to procure 300 million vaccines and sufficient treatments against COVID-19.
“The trial is primarily designed to determine whether AZD1222 can prevent symptomatic COVID-19 after two doses,” the note details, adding that it will also assess whether it can prevent SARS-CoV-2 infection, regardless of symptoms, and severe illness.
Similarly, it will be examined whether the experimental vaccine “can reduce the incidence of visits to the emergency room due to COVID-19.”
Participants, who must be over 18 years of age and previously express their informed consent, will receive two injections of either the vaccine candidate or a saline placebo with an interval of approximately four weeks each.
“One person will receive a placebo injection for every two people who receive AZD1222, resulting in approximately 20,000 people receiving the investigational vaccine and 10,000 receiving a placebo,” the information states.
About, Anthony Fauci, the chief epidemiologist of the US Government and director of the NIAID, assured that “safe and effective vaccines will be essential to meet the global need for widespread protection against COVID-19.”
The US president, Donald Trump, boasted this announcement Monday during a press conference at the White House, and indicated that this vaccine candidate joins another group that “is very close to the end and, hopefully, its approval. ”.
“In the United States we are doing things that nobody thought would be possible. This is a process that in some cases would have taken years and we did it in a matter of months, “said Trump, whose handling of the pandemic has become one of the most criticized points of his management by his Democratic rival in the elections. November, former Vice President Joe Biden.
AstraZeneca’s potential vaccine is in phase 3 of clinical trials, the last one before receiving approval from regulatory authorities.
During clinical trials conducted by Oxford experts, 1,077 volunteers showed that an injection led to the production of antibodies and white cells that can fight the virus.
In June, it was known that this possible vaccine against COVID-19 would also be tested in Brazil.
On August 13, it was also reported that the Mexican industry could start the production of the vaccine against COVID-19 in the first quarter of 2021, after an agreement reached between the Government of Mexico and that of Argentina with AstraZeneca, the University of Oxford and the Carlos Slim Foundation.
The active substance will be developed in Argentina and then shipped to Mexico, where it will be manufactured and later distributed to Latin America, announced Sylvia Varela, president of AstraZeneca Mexico.
The United States reached 6,027,111 confirmed cases of COVID-19 and 183,499 deaths on Monday, according to the independent count from Johns Hopkins University.
This balance at 20.00 local time (00.00 GMT on Tuesday) is 33,443 infections more than on Sunday and 465 new deaths.
Despite the fact that New York is no longer the state with the highest number of infections, it is still the most affected in terms of deaths in the United States with 32,957, more than in France or Spain. In New York City alone, 23,683 people have died.
New York is followed in number of deaths by neighboring New Jersey (15,945), California (13,010), Texas (12,712) and Florida (11,187).
Other states with a large death toll include Massachusetts (9,060), Illinois (8,235), Pennsylvania (7,659), and Michigan (6,753).
In terms of infections, California leads the list with 710,768, followed by Texas with 631,978, Florida with 623,471 and New York with 434,756.
The provisional death toll -183,499- far exceeds the lower limit of the initial estimates of the White House, which in the best of cases projected between 100,000 and 240,000 deaths from the pandemic.
US President Donald Trump lowered those estimates and was confident that the final figure would be between 50,000 and 60,000 deaths, although later he predicted up to 110,000 deaths, a number that has also been exceeded.
For its part, the Institute for Health Metrics and Evaluations (IHME) of the University of Washington, whose models for predicting the evolution of the pandemic are often set by the White House, calculates that for the presidential elections of November 3 The United States will have exceeded 255,000 deaths and by December 1, 310,000.
On the other hand, nearly 1,000 inmates at a Tennessee prison have tested positive for COVID-19, prison authorities reported Monday.
Authorities tested 1,410 inmates at the South Central Region Correctional Center for coronavirus late last week after several inmates and staff members began exhibiting symptoms, the Tennessee Department of Prisons (TDOC for short) reported. in English) in a press release, according to AP.
The post US seeks 30,000 volunteers to test potential AstraZeneca vaccine appeared first on Hispanic World.